Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab for reduction of arterial wall inflammation after acute coronary syndrome
2012-002677-53Phase 2Completed
- Sponsor
- Servier
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gevokizumab in atherosclerosis, arteritis and coronary arteriosclerosis (3 arms), sponsored by Servier. Primary endpoint: Change from baseline in TBR. Started Sep 2012; status: completed.
02
Drugs
gevokizumab
03
Conditions
atherosclerosisarteritiscoronary arteriosclerosis
Beyond the preview
Go deeper on 2012-002677-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002677-53.